NDA 022059 · Novartis
Tykerb
Lapatinib Ditosylate · Oral
NovelAccelerated approvalPriority reviewLast checked: Nov 20, 2026Latest source record: Mar 27, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Mar 13, 2007
Approved uses
5
Original approval plus efficacy supplements
Registered trials
291
41 Phase 3, 5 recruiting
FAERS reports
15,452
10,580 serious, 2,486 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATOTOXICITY Hepatotoxicity has been observed in clinical trials and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain [see Warnings and Precautions (5.2)] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Hepatotoxicity has been observed in clinical trials and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain. ( 5.2 )
What it is approved for
From the label in effect Jan 27, 2026.
TYKERB ® is indicated in combination with: capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. Limitations of Use : Patients should have disease progression on trastuzumab prior to initiation of treatment with TYKERB in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. TYKERB is a kinase inhibitor indicated in combination with: ( 1 ) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. Limitations of Use : Patients should have disease progression on trastuzumab prior to initiation of treatment with TYKERB in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.
Mechanism: Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated K i app values of 3nM and 13nM, respectively) with a dissociation half-life of greater than or equal to 300 minutes. Lapatinib inhibits ErbB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4-tumor cell...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 6, 2018 Supplement 23 · Efficacy LabelLetter
- Oct 18, 2013 Supplement 17 · Efficacy LabelReviewLetter
- Oct 18, 2013 Supplement 16 · Efficacy LabelLetter
- Jan 29, 2010 Supplement 7 · Efficacy ReviewLetterLabel
- Mar 13, 2007 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalLabelReviewLetter
1 products under this application
- TYKERB · LAPATINIB DITOSYLATE EQ 250MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Lapatinib Ditosylate" as an intervention, any sponsor and status, largest first.
- ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00490139 · 8,381 participants · Start May 16, 2007 · Primary completion Dec 6, 2013
Drug: Lapatinib; Trastuzumab · For: Neoplasms, Breast
Sites: Mobile, Alabama; Anchorage, Alaska; Tucson, Arizona · 924 sites in all
- Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast CancerPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00374322 · 3,166 participants · Start Aug 2006 · Primary completion Sep 2011
Drug: lapatinib · For: Neoplasms, Breast
Sites: Tuscaloosa, Alabama; Phoenix, Arizona; Sedona, Arizona · 439 sites in all
- Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast CancerPivotal-lookingCompleted
GBG Forschungs GmbHAcademic, hospital or other
NCT00567554 · 2,600 participants · Start Oct 2007 · Primary completion Aug 2011
Drug: epirubicin - cyclophosphamide / docetaxel; epirubicin - cyclophosphamide / docetaxel + bevacizumab and 4 more · For: Breast Cancer
Sites: Frankfurt am Main, Germany
- Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast CancerPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00073528 · 1,286 participants · Start Dec 9, 2003 · Primary completion Jun 3, 2008
Drug: Lapatinib; Letrozole and 1 more · For: Breast Neoplasms
Sites: Tucson, Arizona; Hot Springs, Arkansas; Jonesboro, Arkansas · 278 sites in all
- Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric CancerPivotal-lookingStatus unknown
Professor David CunninghamGovernment (non-federal)
NCT00450203 · 1,103 participants (planned) · Start Oct 2007 · Primary completion Dec 2017
Drug: bevacizumab; capecitabine and 3 more · For: Oesophagogastric Cancer
Sites: Bournemouth, United Kingdom; Bradford, United Kingdom; Bristol, United Kingdom · 41 sites in all
- A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00829166 · 991 participants · Start Feb 2009 · Primary completion Jul 2012
Drug: Trastuzumab emtansine; Lapatinib and 1 more · For: Breast Cancer
Sites: Chandler, Arizona; Tucson, Arizona; Anaheim, California · 323 sites in all
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentPivotal-lookingRecruiting
Centre Leon BerardAcademic, hospital or other
NCT02029001 · 900 participants (planned) · Start Mar 2014 · Primary completion Jan 2028
Drug: Nilotinib (400 mg BID); Everolimus (10 mg QD) and 4 more · For: Malignant Solid Neoplasms
Sites: Bordeaux, France; Lyon, France; Marseille, France · 7 sites in all
- A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory CancerPivotal-lookingCompleted
Institut CurieAcademic, hospital or other
NCT01771458 · 742 participants · Start Oct 2012 · Primary completion Oct 2016
Drug: Targeted therapy based on molecular profiling : Imatinib; Standard Chemotherapy and 8 more · For: Reccurent/Metastatic Solid Tumor Disease
Sites: Dijon, France; Lyon, France; Marseille, France · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea4,173
- nausea1,616
- death1,463
- fatigue1,309
- vomiting1,211
- rash1,062
- disease progression1,007
- palmar-plantar erythrodysaesthesia syndrome931
- asthenia607
- malignant neoplasm progression565
- drug ineffective561
- dyspnoea561
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 9 |
| 2006 | 14 |
| 2007 | 936 |
| 2008 | 744 |
| 2009 | 1,056 |
| 2010 | 1,246 |
| 2011 | 1,667 |
| 2012 | 1,539 |
| 2013 | 1,479 |
| 2014 | 1,035 |
| 2015 | 1,102 |
| 2016 | 532 |
| 2017 | 721 |
| 2018 | 635 |
| 2019 | 674 |
| 2020 | 706 |
| 2021 | 356 |
| 2022 | 240 |
| 2023 | 253 |
| 2024 | 297 |
| 2025 | 145 |
| 2026 | 66 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tykerb (Lapatinib Ditosylate)
2024 spending
$2.7M
Beneficiaries
62
328 claims
Per beneficiary
$44,043
$64.11 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $27,908,352 |
| 2021 | $7,379,676 |
| 2022 | $3,455,049 |
| 2023 | $2,235,761 |
| 2024 | $2,730,663 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
Sherrill B, Amonkar MM, Stein S, et al. · Br J Cancer 2008 · Clinical Trial, Phase III, Randomized Controlled Trial
- FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
Ryan Q, Ibrahim A, Cohen MH, et al. · Oncologist 2008 · Clinical Trial, Phase III, Multicenter Study
- Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S, Riera Knorrenschild J, Haag GM, et al. · Eur J Cancer 2015 · Clinical Trial, Phase II, Comparative Study
- Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.
Strasser-Weippl K, Horick N, Smith IE, et al. · Eur J Cancer 2016 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.
Schaid DJ, Spraggs CF, McDonnell SK, et al. · J Clin Oncol 2014 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.
Boyle FM, Smith IE, O'Shaughnessy J, et al. · Eur J Cancer 2015 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.